These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 23056637)
1. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. Wu B; Wilson A; Wang FF; Wang SL; Wallace DJ; Weisman MH; Lu LJ PLoS One; 2012; 7(10):e47373. PubMed ID: 23056637 [TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139 [TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803 [TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Spalding JR; Hay J Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Bansback NJ; Brennan A; Ghatnekar O Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533 [TBL] [Abstract][Full Text] [Related]
8. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Hallinen TA; Soini EJ; Eklund K; Puolakka K Rheumatology (Oxford); 2010 Apr; 49(4):767-77. PubMed ID: 20100793 [TBL] [Abstract][Full Text] [Related]
9. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. Doan QV; Chiou CF; Dubois RW J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801 [TBL] [Abstract][Full Text] [Related]
10. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. Davies A; Cifaldi MA; Segurado OG; Weisman MH J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840 [TBL] [Abstract][Full Text] [Related]
14. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232 [TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Lekander I; Borgström F; Lysholm J; van Vollenhoven RF; Lindblad S; Geborek P; Kobelt G Eur J Health Econ; 2013 Dec; 14(6):863-73. PubMed ID: 22990378 [TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918 [TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420 [TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of TNF antagonists in routine clinical practice and costs]. Prokes M Vnitr Lek; 2009 Jan; 55(1):45-53. PubMed ID: 19227955 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642 [TBL] [Abstract][Full Text] [Related]
20. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Tang B; Rahman M; Waters HC; Callegari P Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]